摘要
目的探讨伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性。方法回顾性分析2011年1月至2013年12月采取一线方案氟尿嘧啶联合奥沙利铂(FOLFOX)化疗失败后进行伊立替康联合雷替曲塞治疗的32例晚期结直肠癌患者的临床病例资料,并分析其临床效果、不良反应以及安全性。结果 32例患者病情部分缓解6例,稳定11例,进展13例,中位总生存时间为(13.2±1.1)个月,中位无进展生存时间为(3.7±0.2)个月,最常见的不良反应为疲倦、食欲降低以及中性粒细胞减少,发生率分别为71.9%和68.8%。结论雷替曲塞联合伊立替康对一线治疗失败的晚期结直肠癌患者具有较高的效果,且对不良反应均耐受,该方法值得推荐。
Objective To investigate the efficacy and safety of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer. Methods The clinical data of 32 patients with advanced colorectal cancer treated with irinoteean combined with raltitrexed after the failure of first-line FOLFOX chemotherapy from January 2011 to December 2013 were retrospectively analyzed, and the clinical effects, reactions and safety were analyzed. Results Among the 32 patients, partial remission in 6 cases, stability in 11 cases, diseases progression in 13 cases. The median overall survival time was （13.2 ± 1.1） months, and the median progression-free survival time was （3.7 ± 1.2） months. The most common side effects were fatigue, loss of appetite and neutropenia, the incidence was 71.9% and 68. 8%, respectively. Conclusion Raltitrexedeombined with irinotecan has good effect on first-line treatment of patients with advanced eolorectal cancer, and the toxicity is tolerated, the method should be recommended.
出处
《临床医学》
CAS
2017年第4期12-13,共2页
Clinical Medicine
